Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies [preprint]
Authors
Muecksch, FraukeHou, Shurong
Schiffer, Celia A.
Nussenzweig, Michel
Bjorkman, Pamela J.
Hatziioannou, Theodora
Bieniasz, Paul
Document Type
PreprintPublication Date
2021-03-08Keywords
microbiologySARS-CoV-2
Antibodies
Neutralization
Amino Acids, Peptides, and Proteins
Immunology of Infectious Disease
Microbiology
Virology
Virus Diseases
Metadata
Show full item recordAbstract
Antibodies elicited in response to infection undergo somatic mutation in germinal centers that can result in higher affinity for the cognate antigen. To determine the effects of somatic mutation on the properties of SARS-CoV-2 spike receptor-binding domain (RBD)-specific antibodies, we analyzed six independent antibody lineages. As well as increased neutralization potency, antibody evolution changed pathways for acquisition of resistance and, in some cases, restricted the range of neutralization escape options. For some antibodies, maturation apparently imposed a requirement for multiple spike mutations to enable escape. For certain antibody lineages, maturation enabled neutralization of circulating SARS-CoV-2 variants of concern and heterologous sarbecoviruses. Antibody-antigen structures revealed that these properties resulted from substitutions that allowed additional variability at the interface with the RBD. These findings suggest that increasing antibody diversity through prolonged or repeated antigen exposure may improve protection against diversifying SARS-CoV-2 populations, and perhaps against other pandemic threat coronaviruses.Source
Muecksch F, Weisblum Y, Barnes CO, Schmidt F, Schaefer-Babajew D, Lorenzi JCC, Flyak AI, DeLaitsch AT, Huey-Tubman KE, Hou S, Schiffer CA, Gaebler C, Wang Z, Da Silva J, Poston D, Finkin S, Cho A, Cipolla M, Oliveira TY, Millard KG, Ramos V, Gazumyan A, Rutkowska M, Caskey M, Nussenzweig MC, Bjorkman PJ, Hatziioannou T, Bieniasz PD. Development of potency, breadth and resilience to viral escape mutations in SARS-CoV-2 neutralizing antibodies. bioRxiv [Preprint]. 2021 Mar 8:2021.03.07.434227. doi: 10.1101/2021.03.07.434227. PMID: 33758864; PMCID: PMC7987023. Link to preprint on bioRxiv.
DOI
10.1101/2021.03.07.434227Permanent Link to this Item
http://hdl.handle.net/20.500.14038/29712PubMed ID
33758864Notes
This article is a preprint. Preprints are preliminary reports of work that have not been certified by peer review.
Full author list omitted for brevity. For the full list of authors, see article.
Related Resources
Now published in Cell, doi:10.1016/j.immuni.2021.07.008

